Regeneron Pharmaceuticals Inc.

REGN

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Rock Springs Capital

AI Signal

AI analyst context — unlock full analysis

Catalysts

Phase 2Aug 31, 2023Pexastimogene Devacirepvec (Pexa-Vec)Renal Cell Carcinoma

Phase 2Mar 31, 2025cemiplimabNon-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma

Phase 2

Position Details

Rock Springs CapitalNEWFeb 17, 2026

Shares: 10,100Value: $7.8M

# Signal Note: Rock Springs Capital initiates REGN position Rock Springs' $7.8M stake in Regeneron suggests conviction in near-term catalysts, likely tied to late-stage pipeline milestones (Eylea successor in wet AMD, dupilumab label expansions) or commercial momentum in high-margin franchises. The 10,100 share position size is material for a concentrated manager but represents modest conviction, possibly hedging sector exposure or building ahead of anticipated data readouts in 2024-2025.

More REGN Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

MLYS1 fund NBIX1 fund OLMA1 fund MIRM1 fund AMLX1 fund NAMSW1 fund OMDA1 fund MLTX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer

Phase 3Jul 8, 2025Pozelimab + CemdisiranGeneralized Myasthenia Gravis

Phase 3Jul 17, 2025GaretosmabFibrodysplasia Ossificans Progressiva

Phase 3Aug 26, 2025Aflibercept 8 mgNeovascular Age-Related Macular Degeneration, Diabetic Macular Edema

Phase 2Sep 16, 2025Non-small Cell Lung Cancer (NSCLC)

Phase 2Sep 30, 2025CemiplimabCutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma

Phase 2Nov 30, 2025CemiplimabMetastatic Solid Tumor

Phase 2Dec 15, 2025TirzepatideObesity

Phase 3Dec 29, 20258 mg aflibercept (BAY 86-5321) (High Dose)Diabetic Macular Edema

Phase 2Dec 31, 2025Aspirin ChallengeAspirin-exacerbated Respiratory Disease

Phase 2Jan 31, 2026DupilumabPruritis

Phase 2Feb 1, 2026REGN7544Sepsis-Induced Hypotension

Phase 2Feb 1, 2026UbamatamabRecurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer

Phase 2Feb 18, 2026DupilumabEosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID)

Phase 3Mar 16, 2026FianlimabMelanoma

Phase 2Mar 20, 2026REGN7544Postural Orthostatic Tachycardia Syndrome (POTS)

Phase 2Mar 24, 2026VonsetamigChronic Kidney Disease (CKD)

Phase 2Apr 1, 2026Sarilumab SAR153191 (REGN88)Juvenile Idiopathic Arthritis

Phase 2Apr 17, 2026FianlimabResectable Non-small Cell Lung Cancer

Phase 2Apr 30, 2026CemiplimabColon Cancer

Phase 2May 15, 2026DupilumabColitis Ulcerative

Phase 2May 18, 2026Trevogrumab-Part AObesity

Phase 2Jun 1, 2026REGN9933Venous Thromboembolism

Phase 3Jun 8, 2026DupilumabLichen Simplex Chronicus

Phase 2Jul 6, 2026OdronextamabB-cell Non-Hodgkin Lymphoma (B-NHL)

Phase 3Jul 14, 2026mibavademabGeneralized Lipodystrophy

Phase 2Aug 7, 2026Itepekimab (SAR440340)Chronic Rhinosinusitis Without Nasal Polyps

Phase 2Aug 19, 2026REGN7075Advanced Solid Tumors

Phase 3Oct 7, 2026DupilumabAtopic Dermatitis

Phase 2Oct 20, 2026AlirocumabHypercholesterolemia

Phase 2Nov 2, 2026cemiplimabMelanoma

Phase 2Nov 13, 2026OlatorepatideOverweight or Obesity

Phase 2Nov 30, 2026REGN2810Prostate Cancer Metastatic

Phase 2Nov 30, 2026DupilumabAsthma, Allergic

Phase 3Dec 1, 2026Itepekimab (SAR440340)Chronic Obstructive Pulmonary Disease

Phase 2Dec 31, 2026DegarelixProstate Cancer

Phase 2Dec 31, 2026DupilumabAsthma

Phase 2Dec 31, 2026CemiplimabCarcinoma, Non-Small-Cell Lung

Phase 2Jan 2, 2027OdronextamabFollicular Lymphoma, Lymphoma

Phase 3Jan 8, 2027Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal Polyps

Phase 2Jan 14, 2027REGN4336Metastatic Castration-resistant Prostate Cancer

Phase 3Jan 28, 2027RavulizumabParoxysmal Nocturnal Hemoglobinuria

Phase 2Feb 9, 2027REGN7508Atrial Fibrillation (AF)

Phase 3Feb 20, 2027REGN7508Venous Thromboembolism (VTE)

Phase 3Feb 28, 2027REGN5713Allergic Conjunctivitis

Phase 3Mar 22, 2027fianlimabMelanoma

Phase 2Mar 25, 2027REGN5668Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

Phase 2Apr 30, 2027S095018Non-small Cell Lung Cancer (NSCLC)

Phase 3May 14, 2027OdronextamabB-Cell Non-Hodgkin Lymphoma (B-NHL)

Phase 2May 15, 2027CemiplimabLocally Recurrent Oral Cavity Squamous Cell Carcinoma

Phase 3May 17, 2027REGN7508Symptomatic Venous Thromboembolism (VTE)

Phase 2May 20, 2027CemiplimabNon-Small Cell Lung Cancer

Phase 3Jun 18, 2027MibavademabMonogenic Obesity

Phase 2Jun 30, 2027SNS-101 (anti-VISTA)Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer

Phase 2Jun 30, 2027CemiplimabHPV-Related Squamous Cell Carcinoma

Phase 3Jul 31, 2027nexiguran ziclumeranNeuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease

Phase 2Aug 20, 2027MibavademabFunctional Hypothalamic Amenorrhea (FHA)

Phase 2Aug 31, 2027ErveboEbola Virus Disease

Phase 2Aug 31, 2027CemiplimabNSCLC, Locally Advanced

Phase 2Aug 31, 2027LinvoseltamabMultiple Myeloma

Phase 2Sep 8, 2027ALN-HSDMetabolic Dysfunction-associated Steatohepatitis (MASH)

Phase 2Sep 24, 2027ALN-ANG3Diabetic Kidney Disease (DKD)

Phase 2Sep 30, 2027FianlimabAdvanced Melanoma

Phase 3Oct 20, 2027Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal Polyps

Phase 3Oct 28, 2027DupilumabPrurigo Nodularis

Phase 2Nov 3, 2027DupilumabAlopecia Areata

Phase 2Nov 15, 2027REGN5678Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)

Phase 3Nov 29, 2027PozelimabAge-related Macular Degeneration (AMD), Geographic Atrophy (GA)

Phase 2Dec 1, 2027CemiplimabLung Cancer (NSCLC)

Phase 2Dec 31, 2027Cemiplimab-RwlcNon-small Cell Lung Cancer Stage III

Phase 3Dec 31, 2027NTLA-2001Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Phase 3Dec 31, 2027CemiplimabRecurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

Phase 3Jan 7, 2028CemiplimabCutaneous Squamous Cell Carcinoma

Phase 2Jan 11, 2028REGN13335Pulmonary Arterial Hypertension (PAH)

Phase 2Jan 24, 2028REGN7999Non-Transfusion Dependent Beta-Thalassemia (NTDT)

Phase 2Jan 26, 2028BNT116Advanced Non-Small Cell Lung Cancer

Phase 2Jan 31, 2028CemiplimabColon and Rectal Cancer

Phase 2Jan 31, 2028Encorafenib + BinimetinibMelanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases

Phase 3Feb 7, 2028OdronextamabFollicular Lymphoma (FL)

Phase 3Mar 30, 2028OdronextamabDiffuse Large B-cell Lymphoma (DLBCL)

Phase 2Mar 31, 2028CemiplimabHead and Neck Squamous Cell Carcinoma

Phase 2Mar 31, 2028CemiplimabBladder Urothelial Carcinoma

Phase 2Apr 10, 2028OdronextamabRecurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma

Phase 2Apr 30, 2028Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]Colon Cancer

Phase 3May 16, 2028FianlimabMelanoma

Phase 3May 19, 2028MibavademabGeneralized Lipodystrophy

Phase 2May 31, 2028CemiplimabColorectal Cancer

Phase 2May 31, 2028CemiplimabPleural Mesotheliomas

Phase 2Jun 1, 2028CemiplimabColo-rectal Cancer

Phase 2Jun 4, 2028FDC fianlimab+cemiplimabHead and Neck Squamous Cell Carcinoma (HNSCC)

Phase 3Jun 19, 2028dupilumabEosinophilic Esophagitis (EoE)

Phase 2Jun 28, 2028REGN7041Active Noninfectious Uveitis Affecting the Posterior Segment

Phase 2Jun 30, 2028MotixafortidePancreatic Cancer, Adenocarcinoma of the Pancreas, Adenocarcinoma

Phase 2Jun 30, 2028LinvoseltamabRecurrent Multiple Myeloma, Refractory Multiple Myeloma

Phase 2Jul 31, 2028Cemiplimab Plus GemcitabinePancreatic Ductal Adenocarcinoma (mPDAC)

Phase 2Jul 31, 2028UbamatamabSMARCB1-Deficient Malignancies

Phase 2Aug 20, 2028LinvoseltamabRelapsed/Refractory Systemic Light Chain Amyloidosis

Phase 2Sep 1, 2028SAR444881Solid Tumors

Phase 2Oct 31, 2028CemiplimabBasal Cell Carcinoma (BCC), First Line Treatment

Phase 2Dec 7, 2028UbamatamabOvarian Cancer

Phase 3Dec 12, 2028Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal Polyps

Phase 3Dec 21, 2028DupilumabWheezing, Asthma

Phase 2Dec 31, 2028GemcitabineBladder Cancer, Muscle-Invasive Bladder Carcinoma

Phase 2Dec 31, 2028cemiplimabCutaneous Basal Cell Carcinoma

Phase 3Jan 23, 2029OdronextamabRelapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

Phase 3Jan 31, 2029Dupilumab Prefilled SyringeAsthma Control

Phase 3Feb 26, 2029PozelimabParoxysmal Nocturnal Hemoglobinuria

Phase 3Mar 28, 2029REGN7508Atrial Fibrillation (AF)

Phase 3Mar 31, 2029CemiplimabNon-Small Cell Lung Cancer

Phase 3May 5, 2029REGN7508Peripheral Artery Disease (PAD)

Phase 2May 31, 2029CemiplimabCutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Neoplasms

Phase 3Jun 15, 2029LinvoseltamabRelapsed and/or Refractory Multiple Myeloma (RRMM)

Phase 3Jul 29, 2029OdronextamabFollicular Lymphoma (FL)

Phase 2Aug 31, 2029Cemiplimab 350 MG Intravenous SolutionClear Cell Renal Cell Carcinoma

Phase 2Oct 10, 2029Fianlimab+cemiplimabMelanoma

Phase 3Nov 7, 2029PozelimabParoxysmal Nocturnal Hemoglobinuria

Phase 2Nov 29, 2029ALN-CFBParoxysmal Nocturnal Hemoglobinuria (PNH), Persistent Anemia

Phase 2Nov 30, 2029FianlimabAdvanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC), Clear Cell Renal Cell Carcinoma (ccRCC)

Phase 2Dec 31, 2029Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cyclesMerkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Neoadjuvant Immunotherapy

Phase 3Jan 16, 2030fianlimabNon-small Cell Lung Cancer

Phase 3Jan 23, 2030REGN7508Cancer-Associated Thrombosis (CAT)

Phase 2Feb 3, 2030REGN10597Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors

Phase 3Mar 11, 2030fianlimabAdvanced Non-Small Cell Lung Cancer

Phase 2Apr 30, 2030OxaliplatinColorectal Cancer

Phase 3May 3, 2030CemiplimabCutaneous Squamous Cell Carcinoma (CSCC)

Phase 2Jun 24, 2030UbamatamabAdvanced/Metastatic Non-Small Cell Lung Cancer

Phase 2Sep 30, 2030MaaT033 capsuleNSCLC (Advanced Non-small Cell Lung Cancer)

Phase 2Oct 31, 2030ZIV-AfliberceptMetastatic Uveal Melanoma

Phase 2Apr 19, 2031Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

Phase 3May 1, 2031OdronextamabB-cell Non Hodgkin Lymphoma

Phase 2Jun 5, 2031ALN-SODAmyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene

Phase 2Jul 5, 2031CemiplimabLocally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma

Phase 3Jul 8, 2031REGN7508Venous Thromboembolism (VTE)

Phase 2Apr 22, 2032REGN5093NSCLC

Phase 2May 18, 2032LinvoseltamabMonoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)

Phase 2Dec 2, 2032LinvoseltamabMultiple Myeloma

Phase 2Dec 17, 2032REGV131Hemophilia B

Phase 2Jan 25, 2033LinvoseltamabSmoldering Multiple Myeloma (SMM)

Phase 2Mar 30, 2033LinvoseltamabMultiple Myeloma

Phase 3Apr 19, 2033LinvoseltamabRelapsed Refractory Multiple Myeloma (RRMM)

Phase 3Jul 22, 2033LinvoseltamabHigh Risk Smoldering Multiple Myeloma (HR-SMM)

Phase 2Sep 30, 2033LinvoseltamabRelapsed Refractory Multiple Myeloma (RRMM)

Phase 2Nov 11, 2033LinvoseltamabRelapsed/Refractory Multiple Myeloma

Phase 2Nov 2, 2035LinvoseltamabMultiple Myeloma

Phase 3Dec 31, 2036LinvoseltamabMultiple Myeloma

Phase 3May 21, 2038LinvoseltamabMultiple Myeloma (MM)